OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press14310.17650/1818-8346-2015-10-2-37-45HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯPrevention of neutropenia during chemotherapy by prolonged myelostimulatory preparationsПрофилактика нейтропении при химиотерапии миелостимуляторами пролонгированного действияPtushkinV. V.ПтушкинВ. В.
Russian Federation
vadimvadim@inbox.ruZhukovN. V.ЖуковН. В.
Russian Federation
BorisovV. I.БорисовВ. И.
Russian Federation
MinenkoS. V.МиненкоС. В.
Russian Federation
LarinaYu. V.ЛаринаЮ. В.
Russian Federation
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of RussiaФГБУ «Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России1 Samory Mashela St., Moscow, 117198, Russia S.P. Botkin City Clinical HospitalРоссия, 117198, Москва, ул. Саморы Машела, 1 ГБУЗ «Городская клиническая больница им. С. П. Боткина» Департамента здравоохранения г. Москвы5 , 2nd Botkinskiy Pr-d, Moscow, 125284, Russia N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaРоссия, 125284, Москва, 2-й Боткинский проезд, 5 ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России1 Ostrovityanova St., Moscow, 117997, RussiaРоссия, 117997, Москва, ул. Островитянова, 11 Samory Mashela St., Moscow, 117198, Russia N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaРоссия, 117198, Москва, ул. Саморы Машела, 1 ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава РоссииClinical Oncological Dispensary № 1, Moscow Healthcare DepartmentГБУЗ «Онкологический клинический диспансер № 1» Департамента здравоохранения г. Москвы17/1 Baumanskaya St., Moscow, 105005, RussiaРоссия, 105005, Москва, ул. Бауманская, 17/1S.P. Botkin City Clinical HospitalГБУЗ «Городская клиническая больница им. С. П. Боткина» Департамента здравоохранения г. Москвы5 , 2nd Botkinskiy Pr-d, Moscow, 125284, RussiaРоссия, 125284, Москва, 2-й Боткинский проезд, 51 Samory Mashela St., Moscow, 117198, RussiaРоссия, 117198, Москва, ул. Саморы Машела, 10406201510237450406201504062015https://oncohematology.abvpress.ru/ongm/article/view/143

Neutropenia and associated infection, resulting in hospitalization and use of antibiotics, has a negative effect on chemotherapy. The need to reduce the dose of cytotoxic drugs during neutropenia leads to lower survival rates in patients with hematological malignancies and solid tumors. Since 1990s myelocytokines – proteins that accelerate neutrophil recovery after cytostatic chemotherapy and reduce the risk of infection – is widely used in the clinical practice. The use of these drugs can support the planned dose intensity of chemotherapy and improves the treatment efficacy. The disadvantages of these drugs include the need for their daily parenteral administration for 7–10 days. The development of long-acting forms (pegfilgrastim and lipegfilgrastim) has solved this problem. Self-regulating clearance of prolonged forms allowed to use them only once on a chemotherapy course. Results of pegfilgrastim administration in 25 patients with hematological malignancies (8 patients) and solid tumors (17 patients) included in our analysis. Prolonged preparation showed high efficacy in secondary prophylaxis of neutropenia and infection decreasing the risk by 82 %. The single administration of pegfilgrastim allowed safe dose intensity chemotherapy with shorter intervals between courses (AC-14) in 8 patients with breast cancer. Tolerability was good; cases of hyperleukocytosis have notbeen reported. Recently in Europe and the Russian Federation a new drug from prolonged myelocytokine group – lipegfilgrastim – has been registered. The results of two controlled trials in patients with breast cancer (n = 410) receiving doxorubicin/docetaxel showed high efficacy of the drug as the pegfilgrastim with comparable tolerability.

chemotherapydose intensitytoxicityneutropeniagranulocyte colony stimulating factorpegfilgrastimlipegfilgrastimLonkvexхимиотерапиядозоинтенсивностьтоксичностьнейтропениягранулоцитарный колониестимулирующий факторпэгфилграстимлипэгфилграстимЛонквекс1. Mayordomo J. I., López A., Viñolas N. et al.; ENIA Study Group. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 2009;25(10):2533–42.Mayordomo J. I., López A., Viñolas N. et al.; ENIA Study Group. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 2009;25(10):2533–42.2. Kuderer N. M., Dale D. C., Crawford J. et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106(10):2258–66.Kuderer N. M., Dale D. C., Crawford J. et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106(10):2258–66.3. Elting L. S., Lu C., Escalante C. P. et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008; 26(4):606–11.Elting L. S., Lu C., Escalante C. P. et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 2008; 26(4):606–11.4. Courtney D. M., Aldeen A. Z., Gorman S. M. et al. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist 2007;12(8):1019–26.Courtney D. M., Aldeen A. Z., Gorman S. M. et al. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist 2007;12(8):1019–26.5. Caggiano V., Weiss R. V., Rickert T. S., Linde-Zwirble W. T. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103(9):1916–24.Caggiano V., Weiss R. V., Rickert T. S., Linde-Zwirble W. T. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103(9):1916–24.6. Kozma C. M., Dickson M., Chia V. et al. Trends in neutropenia-related inpatient events. J Oncol Pract 2012;8(3):149–55.Kozma C. M., Dickson M., Chia V. et al. Trends in neutropenia-related inpatient events. J Oncol Pract 2012;8(3):149–55.7. Schilling M. B., Parks C., Deeter R. G. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Exp Ther Med 2011;2(5):859–66.Schilling M. B., Parks C., Deeter R. G. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Exp Ther Med 2011;2(5):859–66.8. Lyman G. H., Dale D. C., Crawford J. Incidence and predictors of low doseintensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21(24):4524–31.Lyman G. H., Dale D. C., Crawford J. Incidence and predictors of low doseintensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21(24):4524–31.9. Mayers C., Panzarella T., Tannock I. F. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;91(12):2246–57.Mayers C., Panzarella T., Tannock I. F. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;91(12):2246–57.10. Adjuvant therapy for breast cancer. NIH Consens Statement 2000;17(4):1–35.Adjuvant therapy for breast cancer. NIH Consens Statement 2000;17(4):1–35.11. Henderson I. C., Berry D. A., Demetri G. D. et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–83.Henderson I. C., Berry D. A., Demetri G. D. et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–83.12. Wood W. C., Budman D. R., Korzun A. H. et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253–9.Wood W. C., Budman D. R., Korzun A. H. et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253–9.13. Chang J. Chemotherapy dose reduction and delay in clinical practice: Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 2000;36(Suppl 1):S11–4.Chang J. Chemotherapy dose reduction and delay in clinical practice: Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 2000;36(Suppl 1):S11–4.14. Bonadonna G., Valagussa P., Moliterni A. et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in nodepositive breast cancer: The results of 20 years of follow-up. N Engl J Med 1995;332:901–6.Bonadonna G., Valagussa P., Moliterni A. et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in nodepositive breast cancer: The results of 20 years of follow-up. N Engl J Med 1995;332:901–6.15. Bonadonna G., Moliterni A., Zambetti M. et al. 30 years , follow up of randomized studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ 2005;330:217–22.Bonadonna G., Moliterni A., Zambetti M. et al. 30 years , follow up of randomized studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ 2005;330:217–22.16. Budman D. R., Berry D. A., Cirrincione C. T. et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998;90:1205–11.Budman D. R., Berry D. A., Cirrincione C. T. et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998;90:1205–11.17 Mayers C., Panzarella T., Tannock I. F. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;91:2246–57.Mayers C., Panzarella T., Tannock I. F. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;91:2246–57.18. Bretzel R. L., Cameron R., Gustas M. et al. Dose intensity in early-stage breast cancer: a community practice experience. J Oncol Pract 2009;5(6):287–90.Bretzel R. L., Cameron R., Gustas M. et al. Dose intensity in early-stage breast cancer: a community practice experience. J Oncol Pract 2009;5(6):287–90.19. Crivellari D., Bonetti M., Castiglione- Gertsch M. et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with reast cancer: The International Breast Cancer Study Group trial VII. J Clin Oncol 2000;18:1412–22.Crivellari D., Bonetti M., Castiglione- Gertsch M. et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with reast cancer: The International Breast Cancer Study Group trial VII. J Clin Oncol 2000;18:1412–22.20. Dees E. C., O , Reilly S., Goodman S. N. et al. A prospective pharmacologic evaluation of ge-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000;18:521–9.Dees E. C., O , Reilly S., Goodman S. N. et al. A prospective pharmacologic evaluation of ge-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000;18:521–9.21. Extermann M., Balducci L., Lyman G. H. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000;18:1709–17.Extermann M., Balducci L., Lyman G. H. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000;18:1709–17.22. Balducci L., Yates J. General guidelines for the management of older patients with cancer. Oncology (Williston Park) 2000;14(11A):221–7.Balducci L., Yates J. General guidelines for the management of older patients with cancer. Oncology (Williston Park) 2000;14(11A):221–7.23. Morrison V. A., Picozzi V., Scott S. et al. The impact of age on delivered dose intensity and hospitalization for febrile neutropenia in patients with intermediate-grade non- Hodgkin, s lymphoma receiving initial chop chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:47–56.Morrison V. A., Picozzi V., Scott S. et al. The impact of age on delivered dose intensity and hospitalization for febrile neutropenia in patients with intermediate-grade non- Hodgkin, s lymphoma receiving initial chop chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:47–56.24. Epelbaum R., Faraggi D., Ben-Arie Y. et al. Survival of diffuse large cell lymphoma. Cancer 1990;66:1124–9.Epelbaum R., Faraggi D., Ben-Arie Y. et al. Survival of diffuse large cell lymphoma. Cancer 1990;66:1124–9.25. Pettengell R., Bosly A., Bron D. Association of reduced dose intensity and survival in lymphoma patients receiving CHOP 21 chemotherapy. Haematologica 2006;91(Suppl 1):69; abstr. 185.Pettengell R., Bosly A., Bron D. Association of reduced dose intensity and survival in lymphoma patients receiving CHOP 21 chemotherapy. Haematologica 2006;91(Suppl 1):69; abstr. 185.26. Crawford J., Ozer H., Stoller R. et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325: 164–70.Crawford J., Ozer H., Stoller R. et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325: 164–70.27. Trillet-Lenoir V., Green J., Manegold C. et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A(3):319–24.Trillet-Lenoir V., Green J., Manegold C. et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A(3):319–24.28. Gisselbrecht С., Haioun C., Lepage E. et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin, s lymphoma: factors influencing chemotherapy administration. Groupe d , Etude des Lymphomes de l ,Adulte. Leuk Lymphoma 1997;25(3–4):289–300.Gisselbrecht С., Haioun C., Lepage E. et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin, s lymphoma: factors influencing chemotherapy administration. Groupe d , Etude des Lymphomes de l ,Adulte. Leuk Lymphoma 1997;25(3–4):289–300.29. NCCN version 2.2015. http://www.nccn.org/.NCCN version 2.2015. http://www.nccn.org/.30. Roskos L. K., Yang B., Schwab G. et al. A cytokinetic model of r-metHuGCSFSD/ 01(SD/01) mediated granulopoiesis and the “self-regulation” of SD/01 elimination in non-small cell lung cancer (NSCLC) patients. Blood 1998;92(Suppl 1): 507a(abstr.).Roskos L. K., Yang B., Schwab G. et al. A cytokinetic model of r-metHuGCSFSD/ 01(SD/01) mediated granulopoiesis and the “self-regulation” of SD/01 elimination in non-small cell lung cancer (NSCLC) patients. Blood 1998;92(Suppl 1): 507a(abstr.).31. Green M. D., Koelbl H., Baselga J. et al. A randomized double-blind multicenter phase III study of fixed-dose singleadministration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29–35.Green M. D., Koelbl H., Baselga J. et al. A randomized double-blind multicenter phase III study of fixed-dose singleadministration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29–35.32. Vose J. M., Crum M., Lazarus H. et al. Single dose pegfilgrastim (SD/01) is as effective as daily filgrastim following ESHAP chemotherapy for subjects with non- Hodgkin , s lymphoma or Hodgkin, s disease: results of a randomized, open label study. Blood 2001;98:799a(abstr. 3322).Vose J. M., Crum M., Lazarus H. et al. Single dose pegfilgrastim (SD/01) is as effective as daily filgrastim following ESHAP chemotherapy for subjects with non- Hodgkin , s lymphoma or Hodgkin, s disease: results of a randomized, open label study. Blood 2001;98:799a(abstr. 3322).33. von Minckwitz G., Kümmel S., du Bois A. et al. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008;19(2):292–8.von Minckwitz G., Kümmel S., du Bois A. et al. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008;19(2):292–8.34. Almenar D., Mayans J., Juan O. et al. Pegfilgrastim and daily granulocyte olonystimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain – results of the LEARN Study. Eur J Cancer Care 2009;18(3):280–6.Almenar D., Mayans J., Juan O. et al. Pegfilgrastim and daily granulocyte olonystimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain – results of the LEARN Study. Eur J Cancer Care 2009;18(3):280–6.35. Kuderer N. M., Dale D. C., Crawford J. et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor in febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158–67.Kuderer N. M., Dale D. C., Crawford J. et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor in febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158–67.36. Lyman G., Dale D., Wolff D. A. et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010;28:2914–24.Lyman G., Dale D., Wolff D. A. et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010;28:2914–24.37. Intragumtornchai T., Sutheesophon J., Sutcharitchan P. et al. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin , s lymphoma. Leuk Lymphoma 2000;37:351–36.Intragumtornchai T., Sutheesophon J., Sutcharitchan P. et al. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin , s lymphoma. Leuk Lymphoma 2000;37:351–36.38. Silber J. H., Fridman M., Shpilsky A. et al. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol 1998;16(7):2435–44.Silber J. H., Fridman M., Shpilsky A. et al. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol 1998;16(7):2435–44.39. EMEA. Guideline on similar biological medicinal products, 2005.EMEA. Guideline on similar biological medicinal products, 2005.40. Buchner A., Elsasser R., Bias P. et al. A randomized, double-blind, active control, multicenter, dosefinding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy. Breast Cancer Res Treat 2014;148(1):107–16.Buchner A., Elsasser R., Bias P. et al. A randomized, double-blind, active control, multicenter, dosefinding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy. Breast Cancer Res Treat 2014;148(1):107–16.41. Bondarenko I., Gladkov O. A., Elsaesser R. et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer 2013;13:386.Bondarenko I., Gladkov O. A., Elsaesser R. et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer 2013;13:386.